AI Article Synopsis
- Accurate measurement of HCV RNA is crucial for treatment monitoring, but previous tests, especially V1 of the Roche COBAS assay, showed underquantification issues in certain genotypes, particularly genotype 4.
- The study analyzed 300 clinical samples using both V1 and V2 versions of the Roche test, revealing that V2 typically produced lower viral load results than V1, with genotype 4 showing the most variation.
- Results indicate that underquantification of genotype 4 samples is uncommon and that specific variants linked to detection issues (nt145 and nt165) are also rare among U.S. samples.
Article Abstract
Background: Accurate HCV RNA measurement is required for monitoring treatment. Underquantification has been reported with some genotypes, particularly genotype 4, using version 1 of the Roche COBAS(®) AmpliPrep/COBAS(®) TaqMan(®) HCV Test.
Objectives: Compare the viral loads of clinical specimens representing diverse genotypes from across the United States using versions 1 (V1) and 2 (V2) of the Roche COBAS(®) AmpliPrep/COBAS(®) TaqMan(®) HCV Test. Assess the frequency of nt145 and nt165 variants in the 5' UTR associated with detection failures and underquantification in a large clinical sample database.
Study Design: Three hundred archived clinical samples were measured using V1 and V2. Bland-Altman analysis was performed on log-transformed results and compared by genotype. The frequencies of nt145 and nt165 variants from 15,817 sequences were calculated.
Results: On average, V2 results were 0.16 logIU/mL lower than V1 results. The average genotype 4 sample was 0.08 logIU/mL higher in V1 than V2. The largest individual sample differences were -2.10 (genotype 2b) and 1.57 (genotype 2a) logIU/mL. For genotype 4 samples, the greatest underquantification by V1 was 1.46 logIU/mL. There were 13 (0.082%) variants at nt145 and 24 variants at nt165 (0.152%), including one sequence with variants at both positions (0.0063%).
Conclusions: Genotype 4 samples from the U.S. are rarely underquantified and not disproportionately so compared to other genotypes using the COBAS(®) AmpliPrep/COBAS(®) TaqMan(®) HCV Tests. Variants at the nt145 and nt165 positions are uncommon in the U.S. and double variants are exceedingly rare. Underquantification of HCV samples with the V1 assay is likely a very rare occurrence in U.S.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcv.2015.02.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Feasibility and staff acceptability of implementing Xpert HIV-1 viral load point-of-care testing: a pilot study in San Francisco.
BMC Infect Dis
January 2025
University of California, San Francisco, San Francisco, CA, USA.
Background: Point-of-care HIV viral load testing may enhance patient care and improve HIV health services. We aimed to evaluate the feasibility and acceptability of implementing such testing in a high-volume community sexual health clinic in the United States.
Methods: We conducted a cross-sectional, mixed-methods study.
Evaluation of the performance of a qPCR-based assay for HIV-1 viral load determination.
PLoS One
December 2024
Department of Anesthesiology, Qilu Hospital of Shandong University, Jinan, Shandong Province, China.
Objective: According to the YY/T 1182-2010 standard of the People's Republic of China on nucleic acid amplification test reagents (kits) for medical industry, the accuracy, precision, linear range, and analytic sensitivity of HIV-1 standardized quality control products should be assessed. The Geneway HIV-1 Nucleic Acid Detection Kit from China has been successfully registered with the National Medical Products Administration. Here, we aimed to assess for the first time its detection performance.
View Article and Find Full Text PDFNucleic acid amplification testing using dried blood spots to confirm the diagnosis of HIV-1 in adults.
J Clin Virol
December 2024
Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Background: The WHO HIV testing algorithm for high prevalence populations recommends the use of three different serologic assays, though this approach may lead to diagnostic misclassification. The study objective was to compare dried blood spot (DBS)-based HIV-1 nucleic acid detection methods to determine their suitability to confirm the diagnosis of HIV-1 in adults generally with suppressed or low-level plasma HIV-1 RNA.
Methods: Four methods were evaluated: Cepheid Xpert HIV-1 Qual Assay (Xpert), Hologic Aptima HIV-1 Quant Dx assay (Aptima), Roche Cobas Ampliprep/Cobas TaqMan HIV-1 test, v.
Diversity, geographical distribution and predictive factors of Hepatitis C virus genotypes and subtypes in Rwanda.
Acta Trop
December 2024
Department of Clinical Microbiology, CHU of Liege, University of Liege - Liege, Belgium. Electronic address:
Background: Existing data on the prevalence of hepatitis C virus (HCV) genotypes and subtypes in Rwanda need to be strengthened. The aim of this study was to identify HCV genotypes and subtypes among HCV-infected patients, as well as their geographical distribution in Rwanda, and to identify the social and economic factors that could influence HCV epidemiology which would make it possible to target national preventive and management actions for infected patients.
Methods: This study included 560 patients with confirmed chronic HCV infection.
Development and field evaluation in African and Asian countries of an hepatitis B virus PCR on open polyvalent platforms to determine treatment eligibility: results from the "Agence Nationale de Recherche sur le Sida et les hépatites" 12327 study.
Clin Microbiol Infect
August 2024
Pathogenesis and Control of Chronic and Emerging Infections, Université de Montpellier, INSERM, EFS, Université des Antilles, Montpellier, France; Department of Virology, CHU de Montpellier, Montpellier, France. Electronic address:
Objectives: Widespread testing and treatment are essential to eliminate hepatitis B virus (HBV) infection as a public health concern. However, in resource-limited countries, access to HBV PCR is limited. In this study, we developed a quantitative HBV PCR assay on open molecular platforms and evaluate its performance in diagnosing clinically significant HBV DNA thresholds as defined by the WHO (2000 IU/mL, 20 000 IU/mL, and 200 000 IU/mL).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!